NGM craters after dropping mid-stage NASH candidate aldaferm...

Shares in NGM Biopharma have plummeted after the US biotech said it would abandon development of aldafermin in non-alcoholic steatohepatitis (NASH), adding to a lengthening list of failed c

Novo Nordisk’s gene silencing alliance with Dicerna bears fi...

Two years after starting to work together, Novo Nordisk and Dicerna have selected the first candidate from a joint project to find new, gene-silencing drugs for liver-related cardiometaboli

Gilead and Novo plot next steps after trial data from NASH c...

Gilead and Novo Nordisk have announced their drug combinations for the fatty liver disease known as NASH checked out in a mid-stage proof-of-concept study.

Genfit abandons late-stage trial of NASH drug elafibranor

France’s Genfit has said its elafibranor drug as a treatment for non-alcoholic steatohepatitis (NASH) was unable to improve patient outcomes in a phase 3 study, which has now b

Another NASH setback as CymaBay drops seladelpar

Novartis takes $80M punt on early-stage NASH drug from Plian...